|1.||Reginster, Jean-Yves: 28 articles (09/2014 - 01/2004)|
|2.||Reginster, J-Y: 15 articles (06/2015 - 01/2002)|
|3.||Reginster, J Y: 14 articles (06/2014 - 02/2001)|
|4.||Roux, C: 9 articles (03/2012 - 12/2002)|
|5.||Blake, Glen M: 8 articles (12/2013 - 06/2005)|
|6.||Fogelman, Ignac: 8 articles (12/2013 - 06/2005)|
|7.||Roux, Christian: 8 articles (04/2012 - 01/2004)|
|8.||Neuprez, Audrey: 7 articles (10/2013 - 08/2006)|
|9.||Boonen, Steven: 7 articles (08/2011 - 10/2005)|
|10.||Rizzoli, René: 6 articles (01/2014 - 01/2004)|
12/01/2008 - "These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient."
01/01/2005 - "The antifracture efficacy of strontium ranelate, 2 g/day orally, an agent that appears to have dissociation effects on resorption and formation, has been assessed in two large, randomized, double-blind, placebo-controlled clinical studies: the Spinal Osteoporosis Therapeutic Intervention (SOTI) trial and the TReatment Of Peripheral Osteoporosis Study (TROPOS), including more than 6,700 postmenopausal women. "
06/01/2010 - "The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors."
02/01/2009 - "The Spinal Osteoporosis Therapeutic Intervention trial established that strontium ranelate decreased the incidence of vertebral fractures, but had little effect on the incidence of non-vertebral fractures. "
12/01/2008 - "The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. "
03/01/2012 - "Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. "
12/01/2009 - "Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. "
09/01/2010 - "Overall, the clinical data available suggest that strontium ranelate is an effective and generally well tolerated option for the first-line treatment of postmenopausal osteoporosis."
04/16/2010 - "Overall, the clinical data available suggest that strontium ranelate is an effective and generally well tolerated option for the first-line treatment of postmenopausal osteoporosis."
02/01/2006 - "The antifracture efficacy of strontium ranelate, 2 g per day orally, in the treatment of postmenopausal osteoporosis has been investigated in a large-scale, international, multicenter, phase 3 program in which more than 7000 patients were recruited. "
12/01/2004 - "Strontium ranelate is a new molecule that both inhibits bone resorption and stimulates bone formation, with proven efficacy to reduce fracture incidence. "
06/01/2006 - "In ovariectomized rats, strontium ranelate decreases bone resorption but maintains high bone formation, resulting in improved bone microarchitecture and increased bone mass and strength. "
02/01/2006 - "These pharmacological and clinical studies suggest that strontium ranelate acts by increasing bone formation and decreasing bone resorption and that these effects result in improved bone mass in vivo."
06/01/2011 - "This review of the most recent pre-clinical and clinical studies is a critical analysis of strontium ranelate's action on bone resorption and formation and how it increases bone mass, microarchitecture and strength in postmenopausal osteoporotic women."
06/01/2011 - "One therapeutic agent, strontium ranelate, was shown to induce opposite effects on bone resorption and formation in pre-clinical studies and to reduce fracture risk in postmenopausal osteoporotic patients. "
06/01/2013 - "Recently, open-label extensions of the SOTI and TROPOS trials up to 8 and, recently, 10 years have confirmed the sustained efficacy of strontium ranelate in increasing BMD, the long-term safety profile and the high compliance to treatment, independently from baseline BMD or other risk factors for osteoporotic fractures. "
02/01/2007 - "Strontium ranelate was shown to be clinically effective in the prevention of osteoporotic fractures. "
10/01/2009 - "Continuous broad protection against osteoporotic fractures with strontium ranelate."
02/01/2003 - "In a phase II study, the effect of strontium ranelate in postmenopausal women with vertebral osteoporotic fractures was assessed during a double-blind, placebo-controlled trial. "
08/01/2011 - "Treatment with strontium ranelate was associated with a significant 31% decrease in all clinical osteoporotic fractures (vertebral fractures included). "
|5.||Hip Fractures (Intertrochanteric Fractures)
11/01/2005 - "The TROPOS study, which aimed at evaluating the effect of strontium ranelate on nonvertebral fractures, showed a significant reduction in the risk of new nonvertebral fractures and also, in a high-risk subgroup, a significant reduction in the risk of hip fractures. "
02/01/2007 - "The evidence base for the efficacy of fracture prevention for strontium ranelate needs to be strengthened, particularly for hip fractures, where there is currently a non-significant reduction. "
04/01/2012 - "The aims of this study were to assess the relationship between hip geometry and the 5-yr risk of hip fractures in postmenopausal osteoporotic women and the effects of strontium ranelate on these parameters. "
05/01/2005 - "This study shows that strontium ranelate significantly reduces the risk of all nonvertebral and in a high-risk subgroup, hip fractures over a 3-yr period, and is well tolerated. "
01/01/2011 - "Strontium ranelate (SrRan) is an anti-osteoporotic treatment that reduces the risk of vertebral and hip fractures. "
|6.||Parathyroid Hormone (Parathormone)
|7.||risedronic acid (risedronate)
|9.||Selective Estrogen Receptor Modulators (SERM)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|3.||Drug Therapy (Chemotherapy)